As previously reported, on 9 April 2024, Novartis and Genentech commenced proceedings in the Dusseldorf Local Division of the UPC (case Numbers: ACT_18492/2024 and ACT_18551/2024) seeking provisional measures against Celltrion in relation to EP 2805248 regarding pharmaceutical formulations of omalizumab, marketed by Novartis and Genentech as Xolair®.
Juve Patent reports that the dispute was heard before four UPC Judges on 31 July 2024, with a judgment to be handed down on 6 September 2024.
Celltrion’s omalizumab biosimilar, Omlyclo® (CT-P39) was the first omalizumab biosimilar to be approved in the UK in early July 2024 and in Europe in May 2024.